Search

Your search keyword '"Hermans, Cedric"' showing total 929 results

Search Constraints

Start Over You searched for: Author "Hermans, Cedric" Remove constraint Author: "Hermans, Cedric"
929 results on '"Hermans, Cedric"'

Search Results

5. The association between unemployment and treatment among adults with hemophilia

7. Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)

8. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

12. The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patients

15. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study

19. A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results.

20. Acquired von Willebrand Syndrome Associated with a Smoldering Multiple Myeloma, Successfully Treated by Daratumumab, Lenalidomide, and Dexamethasone.

21. The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study

24. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

27. Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study

30. Average Nucleotide Identity and Digital DNA-DNA Hybridization Analysis Following PromethION Nanopore-Based Whole Genome Sequencing Allows for Accurate Prokaryotic Typing.

34. The impact of emicizumab on the clinical validation of new therapies for haemophilia A.

39. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review

40. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

41. The value‐based healthcare approach to haemophilia: Development of outcome measures for the evaluation of care of people with haemophilia.

42. The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patients

49. The 2023 Belgian clinical guidance on anticoagulation management in hospitalized and ambulatory COVID-19 patients

50. Emicizumab for acquired haemophilia A: A case series

Catalog

Books, media, physical & digital resources